Evidence map›Paper›PMID 39285643›Full record

ArticleESC heart failure2025

Frailty in heart failure according to the presence or absence of wild-type transthyretin cardiac amyloidosis.

Amaury Broussier, Marie Paugam, Nina Liu, Silvia Oghina, Mounira Kharoubi, Charlotte Lafont, Amira Zaroui, Arnault Galat, Luc Hittinger, Emmanuel Teiger and 3 more

Abstract read
In one paragraph

Article in ESC heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Amaury BroussierINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.ORCID https://orcid.org/0000-0003-1137-9864
Marie PaugamDepartment of Internal Medicine and Geriatrics, AP-HP, Hopitaux Universitaires Henri-Mondor, Creteil, France.
Nina LiuDepartment of Geriatrics, AP-HP, Hopitaux Universitaires Henri-Mondor, Limeil-Brevannes, France.
Silvia OghinaINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Mounira KharoubiINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Charlotte LafontINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Amira ZarouiINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Arnault GalatINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Luc HittingerDepartment of Cardiology, Heart Failure and Amyloidosis Unit, AP-HP, Hopitaux Universitaires Henri-Mondor, Creteil, France.
Emmanuel TeigerDepartment of Cardiology, Heart Failure and Amyloidosis Unit, AP-HP, Hopitaux Universitaires Henri-Mondor, Creteil, France.
Jean Philippe DavidINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Sylvie Bastuji-GarinINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.
Thibaud DamyINSERM, IMRB, Univ Paris Est Creteil, Creteil, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsWild-type transthyretin cardiac amyloidosis (ATTRwt CA) is a common, underdiagnosed cause of heart failure (HF) in the elderly. Concurrent extracardiac amyloid infiltration might be responsible for a specific frailty phenotype. This study aims to compare the prevalence and characteristics of frailty parameters in HF patients, with or without ATTRwt CA.

methodsIn a comparative cross-sectional study, we prospectively included consecutive HF patients with or without ATTRwt CA (the HF + ATTRwt+ and HF + ATTRwt- groups, respectively) between April 2018 and April 2021. Logistic regression models were used to compare the groups with regard to frailty as assessed using multidimensional geriatric tools.

resultsWe included 123 patients (68 HF + ATTRwt+ and 55 HF + ATTRwt-). The mean age was 80.9 (standard deviation 6.3) years, 87% were male, 34% had left ventricular systolic dysfunction and 34% were New York Heart Association (NYHA) III. Relative to the HF + ATTRwt- group, patients in the HF + ATTRwt+ group were more likely to have shrinking [odds ratios = 2.9 (95% confidence interval, 1.1 to 1.7), P = 0.03], balance disorders [1.8 (1.1 to 2.8), P = 0.02], memory complaints [2.5, (1.0 to 5.9), P = 0.05] and overactive bladder [1.5 (1.1 to 2.2), P = 0.03], independently of age, sex, NYHA class and diabetes status. The proportion of very frail patients was higher (albeit not significantly) in the HF + ATTRwt+ group than in the HF + ATTRwt- group [2.4 (0.9 to 6.9), P = 0.10].

conclusionsATTRwt CA is associated with a specific frailty phenotype. Patients with ATTRwt CA should be screened for frailty and managed collaboratively by cardiologists and geriatricians, with a view to improving quality of life.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesFrailtyHeart FailureAgedAged, 80 and overCross-Sectional StudiesFemaleFollow-Up StudiesHumansMalePrevalenceProspective Studiescardiac amyloidosisfrailtyheart failuretransthyretinwild type

Identifiers

PMID39285643
PMCPMC11769631

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.